As of Feb 21, 2025, Regeneron Pharmaceuticals, Inc.'s Discounted Cash Flow (DCF) valuation estimates its share price at $1,274.5. This suggests it may be undervalued by 82.0% compared to its current price of around $700.3, using a WACC of 7.4% and growth rates of 3.0%.
As of Feb 21, 2025, Regeneron Pharmaceuticals, Inc.'s Weighted Average Cost of Capital (WACC) is approximately 7.4%.
As of Feb 21, 2025, Regeneron Pharmaceuticals, Inc.'s Enterprise Value (EV) is approximately $130.8B. This value reflects the company's total market capitalization plus debt, minus cash and cash equivalents, providing a comprehensive measure of its overall value in the market.